Literature DB >> 11972521

Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.

Livio Pagano1, Luana Fianchi, Luca Mele, Corrado Girmenia, Massimo Offidani, Paolo Ricci, Maria E Mitra, Marco Picardi, Cecilia Caramatti, Paolo Piccaluga, Annamaria Nosari, Massimo Buelli, Bernardino Allione, Agostino Cortelezzi, Francesco Fabbiano, Giuseppe Milone, Rosangela Invernizzi, Bruno Martino, Luciano Masini, Giuseppe Todeschini, Maria A Cappucci, Domenico Russo, Laura Corvatta, Pietro Martino, Albano Del Favero.   

Abstract

A retrospective survey was conducted over a 10-year period (1990-99) among 52 haematology divisions in order to evaluate the clinical and laboratory characteristics and outcome of patients with proven Pneumocystis carinii pneumonia (PCP) complicating haematological diseases. The study included 55 patients (18 with non-Hodgkin's lymphoma, 10 with acute lymphoblastic leukaemia, eight with acute myeloid leukaemia, five with chronic myeloid leukaemia, four with chronic lymphocytic leukaemia, four with multiple myeloma, three with myelodysplastic syndrome, two with myelofibrosis and one with thalassemia) who developed PCP. Among these, 18 (33%) underwent stem cell transplantation; only two received an oral prophylaxis with trimethroprim/sulphamethoxazole. Twelve patients (22%) developed PCP despite protective isolation in a laminar airflow room. The most frequent symptoms were: fever (86%), dyspnoea (78%), non-productive cough (71%), thoracic pain (14%) and chills (5%); a severe hypoxaemia was present in 39 patients (71%). Chest radiography or computerized tomography showed interstitial infiltrates in 34 patients (62%), alveolar infiltrates in 12 patients (22%), and alveolar-interstitial infiltrates in nine patients (16%). Bronchoalveolar lavage was diagnostic in 47/48 patients, induced sputum in 9/18 patients and lung biopsy in 3/8 patients. The diagnosis was made in two patients at autopsy. All patients except one started a specific treatment (52 patients trimethroprim/sulphamethoxazole, one pentamidine and one dapsone). Sixteen patients (29%) died of PCP within 30 d of diagnosis. Multivariate analysis showed that prolonged steroid treatment (P < 0.006) and a radiological picture of diffuse lung involvement (P < 0.003) were negative diagnostic factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972521     DOI: 10.1046/j.1365-2141.2002.03419.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  26 in total

Review 1.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

Review 2.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

3.  Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.

Authors:  Michael Scordo; Sejal M Morjaria; Eric R Littmann; Ankush Bhatia; Helen H Chung; Molly Maloy; Lisa M DeAngelis; Sergio A Giralt; Ying Taur; Craig S Sauter
Journal:  Biol Blood Marrow Transplant       Date:  2018-04-18       Impact factor: 5.742

4.  Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients.

Authors:  H A Torres; R F Chemaly; R Storey; E A Aguilera; G M Nogueras; A Safdar; K V I Rolston; I I Raad; D P Kontoyiannis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-06       Impact factor: 3.267

5.  Feasibility of trimethoprim/sulfamethoxazole desensitization therapy in hematological diseases.

Authors:  Shuto Negishi; Kotaro Miyao; Fumiya Ohara; Kenta Motegi; Hiroya Wakabayashi; Hirofumi Yokota; Shihomi Kuwano; Yuki Takeuchi; Hitomi Sawa; Yuichiro Inagaki; Masashi Sawa
Journal:  Clin Exp Med       Date:  2022-08-17       Impact factor: 5.057

Review 6.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Utility of bronchoalveolar lavage in the diagnosis of pulmonary infection in children with haematological malignancies.

Authors:  U Rao; A Piccin; A Malone; K O'Hanlon; F Breatnach; A O'Meara; M McDermott; K Butler; N O'Sullivan; J Russell; A O'Marcaigh; O P Smith
Journal:  Ir J Med Sci       Date:  2012-09-16       Impact factor: 1.568

8.  Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR data demonstrate active replication.

Authors:  M Chabé; E Dei-Cas; C Creusy; L Fleurisse; N Respaldiza; D Camus; I Durand-Joly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-08       Impact factor: 3.267

9.  Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus.

Authors:  Katrien Lagrou; Sharon Chen; Henry Masur; Claudio Viscoli; Catherine F Decker; Livio Pagano; Andreas H Groll
Journal:  Clin Infect Dis       Date:  2021-03-12       Impact factor: 9.079

Review 10.  Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Authors:  S Neumann; S W Krause; G Maschmeyer; X Schiel; M von Lilienfeld-Toal
Journal:  Ann Hematol       Date:  2013-02-15       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.